AU2016244271B2 - Opioid formulations - Google Patents

Opioid formulations Download PDF

Info

Publication number
AU2016244271B2
AU2016244271B2 AU2016244271A AU2016244271A AU2016244271B2 AU 2016244271 B2 AU2016244271 B2 AU 2016244271B2 AU 2016244271 A AU2016244271 A AU 2016244271A AU 2016244271 A AU2016244271 A AU 2016244271A AU 2016244271 B2 AU2016244271 B2 AU 2016244271B2
Authority
AU
Australia
Prior art keywords
buprenorphine
formulation
depot
precursor formulation
depot precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016244271A
Other languages
English (en)
Other versions
AU2016244271A1 (en
Inventor
Ian Harwigsson
Markus Johnsson
Fredrik Tiberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Camurus AB
Original Assignee
Camurus AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53487482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016244271(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/558,463 external-priority patent/US20130190341A1/en
Priority claimed from PCT/EP2013/065855 external-priority patent/WO2014016428A1/en
Application filed by Camurus AB filed Critical Camurus AB
Priority to AU2016244271A priority Critical patent/AU2016244271B2/en
Publication of AU2016244271A1 publication Critical patent/AU2016244271A1/en
Priority to AU2017279657A priority patent/AU2017279657B2/en
Application granted granted Critical
Publication of AU2016244271B2 publication Critical patent/AU2016244271B2/en
Priority to AU2019200982A priority patent/AU2019200982B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
AU2016244271A 2012-07-26 2016-10-13 Opioid formulations Active AU2016244271B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2016244271A AU2016244271B2 (en) 2012-07-26 2016-10-13 Opioid formulations
AU2017279657A AU2017279657B2 (en) 2012-07-26 2017-12-20 Opioid formulations
AU2019200982A AU2019200982B2 (en) 2012-07-26 2019-02-13 Opioid formulations

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13/558,463 2012-07-26
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US201361806185P 2013-03-28 2013-03-28
US61/806,185 2013-03-28
PCT/EP2013/065855 WO2014016428A1 (en) 2012-07-26 2013-07-26 Opioid formulations
AU2013294915A AU2013294915C1 (en) 2012-07-26 2013-07-26 Opioid formulations
AU2016244271A AU2016244271B2 (en) 2012-07-26 2016-10-13 Opioid formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2013294915A Division AU2013294915C1 (en) 2012-07-26 2013-07-26 Opioid formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017279657A Division AU2017279657B2 (en) 2012-07-26 2017-12-20 Opioid formulations

Publications (2)

Publication Number Publication Date
AU2016244271A1 AU2016244271A1 (en) 2016-10-27
AU2016244271B2 true AU2016244271B2 (en) 2018-01-18

Family

ID=53487482

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016244271A Active AU2016244271B2 (en) 2012-07-26 2016-10-13 Opioid formulations
AU2017279657A Active AU2017279657B2 (en) 2012-07-26 2017-12-20 Opioid formulations
AU2019200982A Active AU2019200982B2 (en) 2012-07-26 2019-02-13 Opioid formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017279657A Active AU2017279657B2 (en) 2012-07-26 2017-12-20 Opioid formulations
AU2019200982A Active AU2019200982B2 (en) 2012-07-26 2019-02-13 Opioid formulations

Country Status (20)

Country Link
US (3) US12161640B2 (enExample)
JP (1) JP6417327B2 (enExample)
CN (1) CN109010255B (enExample)
AU (3) AU2016244271B2 (enExample)
CL (1) CL2015000197A1 (enExample)
CY (1) CY1124016T1 (enExample)
DK (1) DK2877155T3 (enExample)
EA (1) EA034855B1 (enExample)
ES (1) ES2837803T3 (enExample)
HK (1) HK1221636A1 (enExample)
HR (1) HRP20210068T1 (enExample)
HU (1) HUE053273T2 (enExample)
IL (3) IL296882A (enExample)
LT (1) LT2877155T (enExample)
MX (2) MX361873B (enExample)
MY (1) MY189481A (enExample)
NZ (2) NZ704012A (enExample)
PE (1) PE20150672A1 (enExample)
PT (1) PT2877155T (enExample)
SG (2) SG10201703964TA (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2877155T (lt) 2012-07-26 2021-02-25 Camurus Ab Opioidų vaisto formos
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
CN111432807A (zh) 2017-10-06 2020-07-17 铸造疗法股份有限公司 用于控制释放治疗剂的可植入贮库
WO2019136490A1 (en) 2018-01-08 2019-07-11 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
EP3793536A1 (en) 2018-05-12 2021-03-24 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
EP3843710A1 (en) 2018-08-28 2021-07-07 Foundry Therapeutics, Inc. Polymer implants
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
GB2618507B (en) * 2021-02-18 2025-02-19 Navin Saxena Research And Tech Private Limited Non-aqueous injectable composition for sustained release of buprenorphine and use thereof
CN117999079A (zh) * 2021-08-20 2024-05-07 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154724A2 (en) * 2010-06-08 2011-12-15 Reckitt Benckiser Healthcare (Uk) Limited Compositions

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
ATE175132T1 (de) 1992-10-26 1999-01-15 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung von mikrokapseln
NZ276305A (en) 1993-11-16 1997-10-24 Depotech Corp Controlled release vesicle compositions
WO1995026715A2 (en) 1994-03-30 1995-10-12 Dumex-Alpharma A/S Use of fatty acid esters as bioadhesive substances
WO1995027481A1 (en) 1994-04-08 1995-10-19 Atrix Laboratories, Inc. Liquid delivery compositions
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
ES2180599T3 (es) 1994-09-30 2003-02-16 Mika Pharma Ges Fur Die Entwic Composicion farmaceutica.
FR2726762B1 (fr) 1994-11-10 1997-01-17 Oreal Composition cosmetique ou dermatologique sous forme d'une dispersion d'une phase huileuse dans une phase aqueuse stabilisee a l'aide de particules de gel cubique et son procede d'obtention
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
CA2231273A1 (en) 1995-10-12 1997-04-17 Lise Sylvest Nielsen A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
SE511313C2 (sv) 1997-01-13 1999-09-06 Gs Dev Ab Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SE9802528D0 (sv) 1998-07-13 1998-07-13 Gs Dev Ab Bone tissue restoring composition
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
JP3952617B2 (ja) 1998-12-11 2007-08-01 株式会社日立製作所 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP4659943B2 (ja) 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US20030003144A1 (en) 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20040022820A1 (en) 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
AU2003240493B2 (en) 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
RU2005134364A (ru) 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) Комбинированное лечение запора
ES2623881T3 (es) 2003-11-07 2017-07-12 Camurus Ab Composiciones de lípidos y péptidos catiónicos
WO2005110360A2 (en) 2004-05-18 2005-11-24 Phares Pharmaceutical Research N.V. Compositions for injection
SG173326A1 (en) 2004-06-04 2011-08-29 Camurus Ab Liquid depot formulations
GB0412530D0 (en) 2004-06-04 2004-07-07 Camurus Ab Formulation
ES2343641T3 (es) * 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
EP1848403B8 (en) 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
US9060935B2 (en) 2005-01-21 2015-06-23 Camurus Ab Pharmaceutical lipid compositions
ES2399645T3 (es) 2005-06-06 2013-04-02 Camurus Ab Formulaciones de análogos de GLP-1
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CA2823407C (en) 2007-03-22 2016-10-18 Berg Pharma Llc Topical formulations having enhanced bioavailability
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8859579B2 (en) 2008-03-21 2014-10-14 Richard Andrew Sewell Compostions and methods for preventing and/or treating disorders associated with cephalic pain
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
WO2010065930A1 (en) 2008-12-04 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
US8975270B2 (en) 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
ES2688577T3 (es) 2010-09-03 2018-11-05 Zoetis Belgium S.A. Composiciones de buprenorfina en dosis altas y uso como analgésico
KR102066755B1 (ko) 2011-05-25 2020-01-15 카무러스 에이비 조절 방출형 펩티드 제형
AU2012348640B2 (en) 2011-12-05 2016-07-21 Camurus Ab Robust controlled-release peptide formulations
LT2877155T (lt) 2012-07-26 2021-02-25 Camurus Ab Opioidų vaisto formos
PL2877155T3 (pl) 2012-07-26 2021-05-17 Camurus Ab Formulacje opioidowe
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
US11920160B2 (en) 2013-02-22 2024-03-05 Cedars-Sinai Medical Center Pancreatic insulin-producing beta-cell lines derived from human pluripotent stem cells
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
MX352907B (es) 2013-03-15 2017-12-13 Heron Therapeutics Inc Composiciones de un poliortoéster y un solvente aprótico.
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
JP6476658B2 (ja) 2013-09-11 2019-03-06 ソニー株式会社 画像処理装置および方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
US10471052B2 (en) 2015-02-19 2019-11-12 Mymd Pharmaceuticals, Inc. Method of treating addictions to opioids
GB201516554D0 (en) 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
RU2729274C2 (ru) 2015-10-28 2020-08-05 Хальдор Топсеэ А/С Дегидрирование этилбензола с получением стирола
EP3863712A4 (en) 2018-10-11 2022-07-20 Indivior UK Limited Buprenorphine to treat respiratory depression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154724A2 (en) * 2010-06-08 2011-12-15 Reckitt Benckiser Healthcare (Uk) Limited Compositions

Also Published As

Publication number Publication date
CL2015000197A1 (es) 2015-11-13
JP2015522649A (ja) 2015-08-06
DK2877155T3 (da) 2021-01-18
MX361873B (es) 2018-12-18
BR112015001548A2 (pt) 2017-07-04
CN109010255B (zh) 2022-10-21
US12161640B2 (en) 2024-12-10
ES2837803T3 (es) 2021-07-01
JP6417327B2 (ja) 2018-11-07
SG11201500554XA (en) 2015-02-27
US20240075024A1 (en) 2024-03-07
PE20150672A1 (es) 2015-05-21
NZ735248A (en) 2018-10-26
US12318379B2 (en) 2025-06-03
US20240226091A9 (en) 2024-07-11
EA034855B1 (ru) 2020-03-30
HUE053273T2 (hu) 2021-06-28
AU2017279657A1 (en) 2018-01-18
HK1205948A1 (en) 2015-12-31
HRP20210068T1 (hr) 2021-03-05
IL236762A0 (en) 2015-03-31
MX2015001033A (es) 2015-04-09
EA201590202A1 (ru) 2015-07-30
IL289157A (en) 2022-02-01
NZ704012A (en) 2017-09-29
AU2019200982A1 (en) 2019-02-28
AU2017279657B2 (en) 2018-11-15
HK1221636A1 (en) 2017-06-09
CN109010255A (zh) 2018-12-18
SG10201703964TA (en) 2017-06-29
US20240131021A1 (en) 2024-04-25
LT2877155T (lt) 2021-02-25
MY189481A (en) 2022-02-16
AU2019200982B2 (en) 2019-07-18
AU2016244271A1 (en) 2016-10-27
MX387722B (es) 2025-03-18
IL296882A (en) 2022-12-01
CY1124016T1 (el) 2022-05-27
US20250049783A1 (en) 2025-02-13
PT2877155T (pt) 2020-12-18

Similar Documents

Publication Publication Date Title
US11110084B2 (en) Opioid formulations
AU2016244271B2 (en) Opioid formulations
US20130190341A1 (en) High bioavailability opioid formulations
HK1205948B (en) Opioid formulations
BR112015001548B1 (pt) Formulação precursora em depósito, composição de depósito, e, uso de uma formulação precursora em depósito

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)